Dr. Luciano Rossetti on the Function of Anti-PD-L1 Treatments in Bladder Cancer

November 18, 2015
Luciano Rossetti, MD

Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.

Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.

Avelumab targets PD-L1 and blocks its interaction with PD-1 and ultimately deters the tumor in paralyzing a patient’s immune response. Rossetti says that anti-PD-L1 therapies are being looked at as monotherapies, first- and second-line therapies, as well as being used in combination with other therapies.